CapitalBio Corporation
CapitalBio Corporation
CapitalBio Corporation (CapitalBio) was established on September 30, 2000, with the support of the State Council of China, the National Development and Reform Commission, the Ministry of Science and Technology, the Ministry of Education, the Ministry of Health and the municipal government of Beijing, relying on Tsinghua University, Huazhong University of Science and Technology, the Chinese Academy of Medical Sciences and the Academy of Military Medical Sciences. It is not only a state-owned innovative high-tech enterprise and enterprise innovation hub in the healthcare industry but also the first national biochip engineering research center operating as an enterprise in China.
Headquartered in Zhongguancun Life Sciences Park, Changping District, Beijing. The group and its subsidiaries have more than 2000 employees, a floor area of over 100,000 square meters dedicated to R&D, production, operation and services, and an annual sales value of over 1.0 billion yuan. On August 12, 2019, Shenzhen Chipscreen Biosciences, an innovative drug research and development company initiated by CapitalBio, was listed on China’s sci-tech innovation board with a record P/E of 467.51x. Currently its market capitalization has reached 19.278 billion yuan.
博奥生物集团有限公司
2000年9月30日，博奥生物集团有限公司(简称博奥生物)在国务院、发改委、科技部、教育部、卫生部、北京市领导的大力支持下，以清华大学为依托、联合华中科技大学、中国医学科学院、军事医学科学院注册成立，是我国医疗健康产业的国有创新型高科技企业，同时也是我国首个以企业化方式运作的国家级生物芯片工程研究中心。
集团总部位于北京市昌平区中关村生命科学园，现有员工2000多人，研发、生产、运营和服务基地建筑面积超过10万平方米，年销售额超过10亿元，在国内拥有北京、上海、重庆、成都、东莞等研发中心和大型产业化基地，并形成了以北京博奥晶典生物技术有限公司(位于北京经济技术开发区)为核心的市场产业化平台。2019年8月12日，集团发起成立的创新药物研发企业深圳微芯生物科技股份有限公司正式上市，以发行市盈率467.51倍创下科创板记录，目前市值192.78亿。
